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Targeting pericranial nerve branches
to treat migraine: Current approaches
and perspectives
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Jean Schoenen2
Abstract
Background: Migraine is a highly prevalent neurological disorders and a major individual and societal burden. Migraine is
not curable at the present time, but it is amenable to acute symptomatic and preventive pharmacotherapies.
Summary: Since the latter are frequently unsatisfactory, other treatment strategies have been used or are being explored.
In particular, interventions targeting pericranial nerves are now part of the migraine armamentarium. We will critically
review some of them, such as invasive and noninvasive neurostimulation, therapeutic blocks and surgical decompressions.
Conclusions: Although current knowledge on migraine pathophysiology suggests a central nervous system dysfunction,
there is some evidence that interventions targeting peripheral nerves are able to modulate neuronal circuits involved in
pain control and that they could be useful in some selected patients. Larger, well-designed and comparative trials are
needed to appraise the respective advantages, disadvantages and indications of most interventions discussed here.
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Introduction
Migraine is one of the most common neurological dis-
orders, aﬀecting 18.5% of the general population (1),
and it causes marked disability in many patients (2,3).
In its episodic form, it is characterized by recurrent
attacks of moderate/severe headache associated with
nausea and/or vomiting, photophobia and phonopho-
bia (4). In 20–30% of patients the headache is preceded
or accompanied at its onset by a sequence of reversible
focal neurological symptoms called ‘‘aura.’’ Classically
it consists of a scintillating scotoma that can be fol-
lowed by sensory and language disturbances and, in
hemiplegic migraine, by motor symptoms.
Episodic migraine may evolve into chronic migraine
when headache days exceed 15 per month with at least
eight migraine headache days (4). Chronic migraine is
the most disabling form of migraine and aﬀects at least
0.5% of the general population (1).
Pathophysiology
Migraine is thought to be a central neurovascular
disorder. The migraine headache is likely generated in
the trigeminovascular system (TVS) (5) that can be acti-
vated by cortical spreading depression (CSD), i.e.
slowly propagating waves of brief neuronal and glial
depolarization followed by prolonged neuronal inacti-
vation (6,7), which is responsible for the migrainous
aura. In migraine without aura the mechanisms under-
lying TVS activation are still controversial, but a role
for dysfunctioning central pain control systems has
been suggested (8). The migraine attack is a sequential
process, comprising in >30% of patients premonitory
symptoms (9,10) accompanied on neuroimaging by
activation in the ventral hypothalamus (11).
The predisposition to attack recurrence in migraine
is reﬂected in functional brain changes that ﬂuctuate
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over the migraine cycle, such as those related to the
processing of sensory stimuli and cortical reactivity
(12), and to mitochondrial energy metabolism
(13–15). Migraine is supposed to be a complex poly-
genic disorder where the genetic load sets a threshold
that is inﬂuenced by environmental and hormonal fac-
tors (16). In chronic migraine there are prominent
changes in cerebral function and structure, many of
which diﬀer from those found in the episodic type
(17). It has been suggested that in some chronic patients
central sensitization ampliﬁes and becomes permanent
(18), which is probably the reason why many preventive
therapies lose eﬃcacy.
Migraine is thus chieﬂy a central nervous system dis-
order. There is nonetheless some circumstantial evi-
dence that the peripheral nervous system might play a
causal or aggravating role in certain migraine patients.
For instance, pericranial tenderness on palpation is well
known in migraineurs (19). In 30% of patients palpa-
tion of scalp trigger points may provoke an attack (20).
In one patient a migrainous headache was suggested to
be due to compression of the lesser occipital nerve by a
lymph node (21). It was recently shown that trigemino-
vascular meningeal aﬀerents project extracranially
through the skull (22) and that activation of these
extracranial aﬀerents in rats causes release of calcitonin
gene-related peptide (CGRP) from the dura, providing
evidence that extracranial noxious signals may inﬂu-
ence meningeal nociception (23). Despite the scarcity
of data favoring a role for extracranial peripheral
nerves in migraine, these nerves have been targeted by
various therapeutic interventions.
Management
The management of migraine patients includes acute
interventions to alleviate the attack and preventive treat-
ments aiming at a reduction of attack frequency and
disability. Acute antimigraine drugs comprise nonster-
oidal anti-inﬂammatory drugs (NSAIDs), simple or
combined analgesics and speciﬁc antimigraine drugs
like triptans and, in some countries, ergots. Analgesics
and speciﬁc antimigraine drugs have a high propensity
to chronify migraine when overused (24). Preventive
drugs have limited eﬃcacy (on average 50%). Many of
them have cumbersome adverse eﬀects (25) and they are
likely to become progressively ineﬀective in chronic
migraine (26) or medication-overuse headache (27).
Alternative treatments have been used for a long
time, but they have received increasing attention
recently, given the lack of new advances in
pharmacotherapy.
We will focus here on interventions that are sup-
posed to act on pericranial nerve branches.
Schematically they can be subdivided into neurostimu-
lations, inﬁltrations/blocks, and surgical
decompressions.
Peripheral neurostimulation
Electrical stimulation of peripheral nerves (PNS) is an
eﬀective way to relieve pain within the territory of the
stimulated nerve. It is possibly due to the activation of
aﬀerent Ab ﬁbers and subsequent gate control mechan-
isms in the spinal cord dorsal horn or/and to the acti-
vation of descending supraspinal controls from
periaqueductal gray and rostroventromedial medulla
(28,29). PNS was initially used in chronic pain syn-
dromes (30), thereafter in occipital neuralgia (31) and
subsequently in migraine prevention (32). The modality
of PNS was often chosen according to the migraine
form, invasive—continuous and applied in the most
severely disabled patients—or noninvasive—intermit-
tent and applicable to all patients.
Invasive PNS
Invasive PNS was explored as preventive therapy quasi-
exclusively in patients suﬀering from drug-resistant
chronic migraine.
Occipital nerve stimulation (ONS). The most studied tech-
nique is greater ONS. Besides small and/or heteroge-
neous open studies, three short-term (i.e. three
months each) randomized, controlled trials (RCTs)
were published (33–35). The Occipital Nerve
Stimulation for the Treatment of Chronic Migraine
Headache (ONSTIM) study (N¼ 66 patients) (34)
showed a reduction of at least 50% in headache fre-
quency and a decrease on the headache intensity scale
in 39% of patients treated with active ONS during 12
weeks, whereas no improvement was found in the
sham-stimulated or medically treated groups.
However, ONSTIM was not powered to convincingly
demonstrate eﬀectiveness of ONS. In the sham-con-
trolled Precision Implantable Stimulator for Migraine
(PRISM) study (33), ONS did not produce any sig-
niﬁcant reduction in headache days in 125 patients
with drug-resistant migraine with or without medica-
tion overuse. Finally, in the largest RCT of ONS in
157 patients with chronic migraine, no diﬀerence was
found between sham and verum groups in the pri-
mary outcome measure (at least 50% reduction in
mean daily headache intensity). However, a higher
percentage of eﬀectively stimulated patients achieved
a 30% reduction in mean headache days (p< 0.05)
and a decrease in migraine-related disability score
(MIDAS) (p< 0.01); 51% of patients stated they
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were satisﬁed with the treatment compared to 19% in
the sham group (35). After the three-month rando-
mized phase, patients continued an open-label phase
of 40 weeks. Monthly headache days were signiﬁ-
cantly reduced by 6.7 days in the intention-to-treat
group, and by 7.7 days in a group of patients with
‘‘intractable’’ chronic migraine (p< 0.01) (36). In a
recent small, randomized, crossover study of eight
patients suﬀering from chronic migraine, suprathres-
hold stimulation was more eﬀective than subthreshold
stimulation, while the latter was superior to no stimu-
lation (37).
These data suggest that ONS may be a promising
treatment option for chronic migraine patients, but
conclusive evidence from large RCTs is still missing.
Moreover ONS can be associated with adverse eﬀects
and complications (local pain, intolerable paresthesias,
local infection, electrode displacement, battery
replacement) and the cost of the device is high
(around 15,000–20,000 euros) while the clinical beneﬁt
seems modest (32).
In a retrospective open study of 44 patients with
chronic migraine, the combination of ONS with supra-
orbital nerve stimulation (SNS) was reported to reduce
the frequency of severe headaches by 81% (38,39). Half
the patients had nearly complete disappearance of
headaches (mean follow-up 13 months) (40), which is
an interesting result that needs to be conﬁrmed in
an RCT.
Vagus nerve stimulation (VNS). Invasive VNS has shown
eﬃcacy in refractory epilepsy. In a retrospective study
of 10 implanted epilepsy patients suﬀering also from
migraine, eight had at least a 50% reduction in head-
ache frequency six months after starting VNS (40).
Other observational VNS studies included small num-
bers of patients, but reported overall an improvement
in 50% of patients (32).
Non-invasive PNS
Compared to the invasive methods described above,
noninvasive PNS can in theory be applied to any
patient, including the less-disabled ones.
Transcutaneous supraorbital nerve stimulation (tSNS). The
eﬀectiveness of the portable tSNS Cefaly for
migraine prophylaxis has been recently evaluated
in a randomized, double-blind sham-controlled trial
(41). Sixty-seven episodic migraineurs were treated
with daily tSNS or sham sessions of 20 minutes
for three months. Compared to baseline, the mean
monthly number of migraine days had signiﬁcantly
decreased after three months in the tSNS (6.94 3.04
vs. 4.88 3.46; p< 0.05), but not in the sham
group (6.54 2.61 vs. 6.22 2.99; p¼ ns). The
50% responder rate was signiﬁcantly greater in the
tSNS (38.1%) than in the sham group (12.1%,
p< 0.05). Acute antimigraine drug intake was also sig-
niﬁcantly reduced in the verum but not in the sham
group.
In an Internet survey of participants in the general
population renting the tSNS Cefaly device before
deciding to buy it or not (42), a majority (54.4%) of
2313 individuals declared themselves satisﬁed and
decided to keep the device (average testing period:
58.2 days). Among the unsatisﬁed patients (46.6%),
the built-in monitoring system of the time the device
was used showed poor compliance (tSNS used 48.6%
of the recommended time, 4.46% of patients did not
even switch the device on). Only 4.3% of individuals
reported one or more adverse event(s) such as local
pain/intolerance to paresthesia (2.03%), arousal
changes (0.82%), and headache after the stimulation
(0.52%). A transient local skin allergy was seen in
0.09%.
There is no RCT of this device for the abortive treat-
ment of migraine attacks.
Transcutaneous VNS. New devices thought to stimulate
the vagus nerve transcutaneously (tVNS) have
recently been developed and their eﬃcacy as acute
and preventive treatments of primary headaches is
being evaluated. Preliminary open data in 30 patients
suggest that the Gammacore device targeting
the tVNS in the neck was eﬀective in aborting migraine
attacks, 21% of patients being pain free at two
hours (43).
In a randomized, sham-controlled pilot study of
chronic migraine patients (44), two months of three
daily 90-second stimulations produced at least a 50%
reduction in headache days in four out of 26 patients
(15%), compared to none out of 23 in the sham-stimu-
lated group. This modest beneﬁcial eﬀect was con-
ﬁrmed in the subsequent open-label phase (45), but
further studies are clearly needed to determine the
role of tVNS in migraine management. Besides neck
muscle contractions in some patients, there were no
signiﬁcant adverse eﬀects.
Conclusion
Invasive ONS still awaits deﬁnitive proof of eﬃcacy
and could be envisaged only after failure or intolerance
of several preventive antimigraine drugs in chronic
migraine suﬀerers (46). In medication overuse headache
patients, it is crucial to detoxify before considering any
invasive neurostimulation, as drug overuse seems to be
Ambrosini et al. 3
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associated with a less favorable outcome with ONS
(47). Patients must be aware that outcome is uncertain,
and that improvement may be moderate.
Noninvasive PNS, especially tSNS, can be proposed
to less-disabled migraineurs as preventive or add-on
migraine therapy (42). Although evidence of beneﬁt is
lacking, tSNS and tVNS could also be proposed as add-
on to drug-resistant chronic migraine patients, before
turning to more invasive and expensive devices (48).
Because of the paresthesias they produce, it is
notoriously diﬃcult to correctly blind PNS trials.
Appropriate RCTs are mandatory, the more so that
the placebo response is greater with devices than with
oral drug therapies (49). More studies are needed to
verify that subthreshold stimulations can be adequately
used as controls and to establish dose-response curves
(32,35).
The studies performed up to now with the noninva-
sive devices indicate that compliance may be the real
challenge to solve in RCTs and in clinical practice (45).
Infiltrations/blocks of pericranial nerves
Many studies have been performed in the past decades
to evaluate the eﬀects of inﬁltrations or ‘‘blocks’’ in the
region of the greater occipital nerve (GON) in migraine,
both as preventive or acute treatment. The rationale for
such treatments is the anatomo-physiological conver-
gence of C2 dermatoma and trigeminovascular aﬀer-
ents in the spinal trigeminal nucleus underlying
referred pain from the neck and orbitofrontal regions
innervated by the ophthalmic nerve (50).
The major studies are summarized in Table 1
(51–62). Unfortunately, there are very few controlled
trials and no standardized methods were used for the
selection of migraine patients (some had ﬁxed unilateral
headache, others not), the timing of inﬁltrations (ictal
or interictal), the technique of inﬁltrations or blocks
(unilateral or bilateral, association with blocks of
other pericranial nerves or trigger point injections,
one or more interventions), the compounds used for
the blocks (local anesthetics alone or combined with
diﬀerent types and dosages of steroids) and particularly
the evaluation of outcomes (number of headache-free
days, variable percentage reduction of headache days
or attacks, non-uniformly standardized pain indices).
The great heterogeneity of published studies therefore
renders their evaluation diﬃcult.
Overall, a complete or partial beneﬁcial preventive
eﬀect was reported in 48–100% of adult migraineurs,
lasting from a few days to several months. A retrospect-
ive study also found partial beneﬁt (<35%) from GON
injections in pediatric chronic migraineurs (60). In one
controlled, single-blinded study the addition of steroids
for GON blocks was not superior to the anesthetic drug
alone (56). Similarly, in one recent placebo-controlled,
randomized, double-blinded trial (61) comparing GON
injections with 2.5ml 0.5% bupivacaine plus 0.5ml
(20mg) methylprednisolone to blocks with 2.75ml
normal saline plus 0.25ml 1% lidocaine in episodic
(n¼ 54) and chronic (n¼ 9) migraineurs (verum group
n¼ 33; placebo group n¼ 30), the blocks with steroids
showed no superiority over placebo.
By contrast, in another recent double-blind, placebo-
controlled study of suboccipital blocks in 72 chronic
migraine patients—available at present only in abstract
form—comparing four weekly injections of saline to
0.5% bupivacaine (62), the number of headache days
decreased from 16.9 5.7 days to 13.2 6.7 days in the
former (p¼ 0.035) but from 18.1 5.3 days to 8.8 4.8
days (p< 0.001) in the latter, and the superior eﬀect of
bupivacaine was conﬁrmed in an open two-month
extension study. Medication overuse tripled the risk
of failure of the treatment in one study (58) but had
no inﬂuence on outcome in two other ones (55,59). In
many studies palpation tenderness in the GON region
was taken intuitively as a criterion for selecting patients
for GON blockade/inﬁltration. The positive predictive
value of GON tenderness was assessed in two inde-
pendent studies with divergent results: It was associated
with better outcome in the ﬁrst (55), but not in the
second (59).
GON blocks were also tested as a symptomatic
treatment for acute migraine headache. Combined lido-
caine blockade of GON and supraorbital (SO) nerves in
14 patients produced only negligible pain reduction
(6%) after 30 minutes; 50% of patients did not respond
at all (63). By contrast, in an open study of 25 patients
with unilateral migraine (11 episodic and 14 chronic)
and brush allodynia, a GON block with 1 cc of a 50/50
mixture of 2% lidocaine and 0.5% bupivacaine reduced
headache intensity by a mean of 46.8% in 89.5% of
patients after 20minutes and ipsilateral allodynia by a
mean of 65.7% in all patients (64). The same procedure
reduced the pain and allodynia scores respectively by
64% and 75% after ﬁve minutes (65). The mean dur-
ation of beneﬁt in these studies was four days, both in
episodic and chronic migraineurs. In a case report, a
woman aﬀected by basilar migraine underwent GON
inﬁltration with 3ml of 0.25% bupivacaine and 1ml of
40mg/ml triamcinolone and reported after a few min-
utes partial resolution of the aura symptoms and com-
plete disappearance of the headache (66).
It is diﬃcult to assess whether SO nerve blocks are
eﬀective, as they have rarely been studied in isolation.
In the study by Bovim and Sand (1992) (63), the com-
bination of GON and SO nerve blocks with 0.5–1.5ml
of lidocaine (20mg/ml and 12.5mg /ml adrenaline) was
not eﬀective. By contrast, in another study comparing
SO and GON blocks alone and the combination of
4 Cephalalgia 0(0)
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both, after SO blocks solely (54) a 50% improvement of
headache frequency was found in 68.75% of patients
after one month and in 75% of patients after six
months. Recently, three consecutive bilateral SO and
infraorbital nerve blocks with 1.5ml of 1% lidocaine
in episodic migraine patients were reported to signiﬁ-
cantly reduce mean headache frequency and MIDAS
score (67).
To conclude, although inﬁltrations with steroids and
anesthetic blocks of cranial nerves have been exten-
sively used in migraine patients for a long time and
eﬀectiveness was reported in many observational stu-
dies, there are only two RCTs available: in one of them,
comparing saline to bupivacaine in chronic migraine
(62), the eﬀect of bupivacaine exceeds that of placebo,
but in the other, where bupivacaine plus methylpredni-
solone was compared to saline plus lidocaine, both
groups had similar outcomes. Adverse eﬀects reported
after peripheral nerve blocks are rare and minor
(see Table 1). Further studies are needed to determine
in which subgroups of migraine patients suboccipital or
SO nerve blocks are superior to placebo.
Surgical decompressions
As mentioned above, there is scarce evidence that ner-
vous structures in the pericranium or face play a pri-
mary causative role in migraine pathogenesis. Many
patients nevertheless refer their pain to the surface of
the head or neck in close anatomical relationship with
branches of pericranial nerves. Although these superﬁ-
cial pain locations are nowadays merely attributed to
referred pain from the visceral part of the ophthalmic
nerve, surgical attempts to treat migraine by acting dir-
ectly on cranial nerves have been published as case
reports as early as the ﬁrst half of the 20th century (68).
More recently, decompression of pericranial nerves
by sectioning neighboring muscles and sections of
superﬁcial nerve branches were proposed as therapeutic
options for migraine patients. The bulk of data con-
cerning these procedures originates from Guyuron’s
group in Cleveland (see Table 2) (69–81). These authors
ﬁrst studied retrospectively patients who underwent
resection of corrugator supercilii muscle for rejuven-
ation and reported improving or disappearance of
their headaches (69). This was followed by a prospect-
ive study on 29 patients with hypertrophy of the
corrugator supercilii muscle and at least 50% amelior-
ation by one injection of 25 U of botulinum toxin
type A into this muscle (70). Twenty-four patients out
of 29 responded to botulinum toxin, 16 having com-
plete disappearance of headaches, and eight partial
improvements. The complete responders underwent a
corrugator supercilii muscle resection while the
others had in addition a transection of the
zygomaticotemporal branch of the trigeminal nerve
and repositioning of the temple soft tissues. After
follow-up (222–494 days), all patients except one
improved; 10 out of 22 operated patients were pain
free. Assuming that various pericranial trigger sites
might play a role in migraine and that they can be
identiﬁed by local botulinum toxin injections, the
same group in a subsequent unblinded prospective
study (71) allocated patients to one of a combination
of four surgical techniques and followed a nonoperated
on control group of 25 patients for one year.
Depending on the origin of pain and botulinum toxin
eﬀect, the surgical procedures were 1) removal of cor-
rugator supercilii, depressor supercilii and procerus mus-
cles (90% of patients); 2) endoscopic removal of 3 cm of
the zygomaticotemporal branch of the trigeminal nerve
(80%); 3) resection of the semispinalis capitis muscle
and shielding of the greater occipital nerve (38%); 4)
septoplasty and inferior and/or middle turbinectomies
(70%). Ninety-two percent of the operated patients
were reported to have at least 50% reduction in
migraine headache frequency and duration, while only
15.8% of controls improved. There was also a signiﬁ-
cant eﬀect on quality of life, work loss and cost for
migraine care in the operated group.
In the ﬁve-year follow-up of the patients included in
this study (75), out of 69 patients who completed it
without re-interventions, six were operated at one site,
15 at two, 30 at three and 18 at all four trigger sites.
Eighty-eight percent of patients reported beneﬁcial
eﬀects from the surgical treatment at the end of the
ﬁve-year follow-up: disappearance of headache in
29%, a 50% reduction in 59%.
In the only sham-controlled study (74), 130 patients
with ‘‘frequent moderate to severe migraine’’ with or
without aura were included on the basis that they
reported a so-called ‘‘trigger site,’’ i.e. a predominant
site ‘‘where the migraine headache begins and settles
and corresponds to the anatomical zone of potential irri-
tation of the trigeminal nerve.’’ Among them, 75 were
included in the study because they had at least 50%
amelioration after injection of 25 U botulinum toxin
into the ‘‘trigger’’ area and completed a one-year
follow-up. They were divided into three groups accord-
ing to the localization of the ‘‘trigger’’ site: frontal, tem-
poral or occipital. The ‘‘frontal’’ group underwent the
above-mentioned procedure 1, the ‘‘temporal’’ group
procedure 2, and the ‘‘occipital’’ group procedure 3. In
each group a third of patients underwent a sham opera-
tion. In the verum arm (n¼ 49) 83.7% of participants
from the three groups reported a signiﬁcant amelior-
ation or elimination of headaches, whereas in the sham
arm (n¼ 26) 57.7% had a similar positive outcome.
More recently, the same group published several
retrospective studies aiming at identifying predictors
Ambrosini et al. 7
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of favorable outcome (76,78,80) or added value of add-
itional surgical procedures like supraorbital foraminot-
omy (79) or ligation of the occipital artery (81).
Only three other groups have published retrospective
studies on the eﬀects of surgery in the frontal area in
migraine. In the largest study (72) resection of the cor-
rugator and depressor muscles in 60 episodic or chronic
migraineurs, a 50% reduction in headache days at a
six-month-follow-up was found in 58.3% of patients,
most of them having a mild form of migraine. In
another study (73) 16 out of 18 migraine patients
responding to botulinum toxin and operated on at mul-
tiple sites in various combinations had a 50% ameli-
oration of migraine headaches at a mean follow-up of
16 months. In 10 patients suﬀering from frontally
located ‘‘chronic daily headache’’ (77) and ameliorated
by 50% after at least two frontal injections of botu-
linum toxin, nine had 50% improvement after corru-
gator muscle resection.
The rationale for surgical decompression of pericra-
nial nerves in migraine is that compression of periph-
eral nerves induces inﬂammation and peptide release
that may reach the meninges and hence trigger migraine
headaches. Though still speculative, this rationale may
gain support from recent studies demonstrating extra-
cranial projections of meningeal aﬀerents (22).
One weakness of peripheral nerve decompressions is
that the evidence comes from retrospective or prospect-
ive uncontrolled studies with only one exception. The
migraine patients included in these studies all had some
uncommon clinical characteristics (82), such as strictly
localized and side-locked headache and the presence of
‘‘trigger sites’’ that are more typical of cranial neural-
gias and tension-type headaches (4). Also, the ‘‘constel-
lation of symptoms’’ by which the authors classify
patients in order to operate on speciﬁc sites are
common to other primary or secondary headaches
like neuralgias, headaches attributed to temporoman-
dibular dysfunction, chronic tension-type headache,
chronic/recurring rhinosinusitis, mucosal contact
points or concha bullosa, and whiplash. Many of
these head pains may coexist with and/or aggravate
migraine and their alleviation could indirectly cause
clinical improvement in migraineurs.
Another puzzling observation in published studies
concerns the selection of patients. Most of them were
diagnosed as episodic migraineurs. Botulinum toxin
type A injections at ‘‘trigger sites’’ reduced headache
frequency by at least 50% in 58% and 90% of patients
(70,71,74,75), which clearly contrasts with the much
lower responder rate (maximum 30%, not signiﬁcantly
diﬀerent from placebo) in RCTs of botulinum toxin in
episodic migraine (83). As the placebo response has been
very high in all botulinum toxin trials (84,85), this may
have favored the selection of placebo responders.
In the sole sham-controlled study of peripheral nerve
decompression, the placebo response was particularly
high (58%), possibly because of the possibility that the
incision and the undermining of pericranial tissues may
have altered neurosensory functions and that some
patients may have exaggerated their preoperative symp-
toms to increase their chance of selection for surgery
(70,71,74,77). In fact, the placebo response is in general
higher with invasive than with drug treatments (49).
The resulting therapeutic gain of 25% may appear
clinically useful in very disabled patients, but in most
published decompression studies there is no informa-
tion about concomitant or previous preventive drug
treatments or refractoriness to them.
Because of these confounding and atypical features
surgical decompression of PNS cannot be considered as
an established treatment option for migraineurs in gen-
eral, although it may be useful in a subgroup of patients
after careful weighing of possible side eﬀects (see
Table 2) and cost. Independent sham-controlled studies
coming from diﬀerent research groups and using stan-
dardized procedures for patient selection are war-
ranted, including comparisons with optimized medical
therapy.
Conclusions
Acting on pericranial nerve branches to treat migraine
is not novel. Although current knowledge of migraine
pathophysiology favors a central nervous system dys-
function (12), there is some evidence that interventions
targeting PNS are able to modulate neuronal circuits
involved in central sensitization and pain control.
Invasive or noninvasive neurostimulation, anesthetic/
steroid blocks, and surgical decompression of pericra-
nial nerves may act in this way, which suggests that
their eﬀect is merely symptomatic.
Advances in this therapeutic area will come from a
better knowledge of migraine pathophysiology, more
precise phenotyping of patients and advances in tech-
nology and treatment protocols. Larger, better-
designed and comparative trials are needed to appraise
the respective advantages, disadvantages and indica-
tions of most interventions discussed here. Such trials
may be diﬃcult to set up for treatments like nerve
blocks for which there is no commercial interest.
The challenge will be to use comparable standards
for the evaluation of their eﬀects in drug trials and to
manage adequately the blinding caveat.
Literature search methods
English-language publications were searched for in
PubMed up to July 2014, and updated in December
2014.
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The following search terms were used: ‘‘migraine
neurostimulation,’’ ‘‘migraine neuromodulation,’’
‘‘migraine injection,’’ ‘‘migraine nerve inﬁltrations,’’
‘‘migraine nerve blocks,’’ ‘‘migraine surgery’’ and
‘‘migraine decompression.’’ All the identiﬁed publica-
tions were individually assessed according to their
relevance to the topic. Speciﬁc exclusion
criteria included: publications on single case reports,
editorials and other review articles unless of excep-
tional importance. The reference lists of identiﬁed pub-
lications were also scrutinized for further relevant
publications.
Clinical implications
. The deﬁnitive evidence that percutaneous occipital nerve stimulation (ONS) is eﬀective in chronic migraine
has not been obtained yet, but some randomized controlled trials (RCTs) indicate nonetheless that ONS
might ameliorate a subgroup of patients.
. Noninvasive transcutaneous supraorbital neurostimulation is superior to sham stimulation for the preven-
tion of episodic migraine, and noninvasive vagus nerve stimulation in the neck is promising for chronic
migraine. Technological advances and improved stimulation protocols may improve performance of these
methods in the near future. Further study results are eagerly awaited.
. Since it is inexpensive and safe and there are some indications from observational studies for its usefulness,
suboccipital inﬁltration may be an add-on option in selected patients, in particular those with ﬁxed unilat-
eral headaches and ipsilateral autonomic symptoms. Convincing evidence for eﬃcacy from RCTs is, how-
ever, missing.
. Surgical decompression of pericranial nerves was found superior to sham surgery in one study and most
published case reports are from the same group. Because of the heterogeneity of patients included, selection
bias and the questionable inclusion criteria, the eﬃcacy and usefulness of surgical decompressions in
migraine patients cannot be considered as deﬁnitely established until other RCTs from other independent
groups conﬁrm it.
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